MEDNAX

Pediatrix Medical Group, Inc. engages in the provision of physician services. It includes newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care. The company was founded by Roger J. Medel in 1979 and is headquartered in Sunrise, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MEDNAX reports stable Q4 performance, eyes in-network growth opportunities

MEDNAX's Q4 call highlighted stable performance, strategic focus on core areas, and challenges from R1 transition and labor inflation. Opportunities in payer relationships, acquisitions, and organic growth are key for future success.

MEDNAX (MD) reports solid Q1 performance, eyes growth opportunities

MEDNAX's Q1 2023 performance showcased stability in patient volumes, pricing strength, and effective cost management. The company's focus on revenue cycle management and debt reduction yielded positive outcomes. Addressing challenges and seizing growth opportunities will be key for sustained success.

MEDNAX (MD) reports strong Q2 performance and eyes growth opportunities

MEDNAX (MD) delivers a solid performance in Q2 2023 with stable patient volumes, strong pricing, and cost efficiencies. The company's focus on improving AR collections, expanding clinics, and potential acquisitions positions it well for future growth.

MEDNAX reports Q3 earnings below forecast, revises full-year outlook

MEDNAX acknowledges disappointing Q3 results, plans structural changes to address challenges, and revises full-year adjusted EBITDA outlook. Despite facing operational challenges, the company shows strength in managing cash and negotiating subsidies with hospital partners.

MEDNAX meets Q4 expectations, eyes stable growth and cost efficiencies

MEDNAX's Q4 performance met expectations, with a focus on stabilizing margins and narrowing financial performance range. The company is poised for stable revenue growth in 2024, with opportunities to deploy capital for acquisitions and improve cost efficiencies. Challenges include stabilizing margins and addressing modest revenue growth expectations.

MEDNAX reports strong Q1 results, accelerates restructuring for growth

MEDNAX's Q1 performance reflects positive revenue growth and operational efficiency initiatives. While facing challenges in communicating practice exits and financial impacts, the company is well-positioned to capitalize on growth opportunities in core services. By focusing on restructuring and maintaining financial discipline, MEDNAX aims to drive continued progress throughout 2024.

MEDNAX surpasses Q2 expectations, focuses on strategic realignment for growth

MEDNAX's Q2 performance exceeded expectations with revenue growth and cost efficiencies driving results.
While facing challenges from restructuring, the company aims to capitalize on opportunities for margin improvement.
Maintaining financial outlook, appointing new leadership, and strategic shifts position MEDNAX for future growth.
Overall, MEDNAX's focus on operational enhancements and strategic realignment bode well for its financial health.

MEDNAX surpasses Q3 expectations with strategic initiatives driving growth

MEDNAX delivered strong Q3 performance with revenue growth, stable patient volumes, and successful operational transitions.
Strategic initiatives like portfolio restructuring and improved liquidity position highlight the company's focus on long-term sustainability.
While challenges like executing restructuring plans and managing liquidity exist, opportunities for growth and value creation are also present.
Overall, MEDNAX's financial outlook remains positive, supported by operational efficiency and prudent financial management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Community Health Systems

HCA Healthcare

High patient volumes, mergers and buyouts, and demand for virtual health services are likely to help hospital companies like THC, HCA and CYH.

3 Hospital Stocks That Crushed S&P 500 YTD, Set to Rise Further

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Mednax to Present at Bank of America 2021 Leveraged Finance Conference

Mednax to Present at Bank of America 2021 Leveraged Finance Conference

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Mednax to Present at Credit Suisse 30th Annual Healthcare Conference

Mednax to Present at Credit Suisse 30th Annual Healthcare Conference

MEDNAX's (MD) third-quarter results reflect growing revenues driven by rising patient volumes, partly offset by higher general and administrative expenses.

MEDNAX's (MD) Q3 Earnings Beat Estimates, Revenues Up Y/Y

MEDNAX, Inc. (MD) CEO Mark Ordan on Q3 2021 Results - Earnings Call Transcript

Mednax (MD) delivered earnings and revenue surprises of 9.52% and 2.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Mednax (MD) Q3 Earnings and Revenues Surpass Estimates

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Mednax Reports Third Quarter Results

Mednax Reports Third Quarter Results

ACADIA Pharma

Acadia Healthcare

Anthem

Teladoc

Tenet Healthcare

UnitedHealth Group

Vertex Pharmaceuticals

Factors like an aging populace and demand for products and services are likely to reflect on the Q3 results of ACAD, MD, ACHC and VRTX.

4 Healthcare Stocks to Top Q3 Estimates Amid Coronavirus Woes

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Mednax (MD) is a Top Growth Stock for the Long-Term

Mednax (MD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mednax (MD) Earnings Expected to Grow: Should You Buy?

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Mednax 2021 Third Quarter Conference Call/Webcast Scheduled for Thursday, October 28, 2021

Mednax 2021 Third Quarter Conference Call/Webcast Scheduled for Thursday, October 28, 2021

Mednax utilizes NextGen's (NXGN) fully-integrated platform to enhance its efficacy in placing crucial information on patients' health and well-being at the physician's fingertips.

NextGen's (NXGN) Integrated Platform Gets Leveraged by Mednax

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Mednax provides full support of the CDC and other medical associations' recommendations that all eligible Americans be vaccinated against COVID-19.

Mednax Clinical Leadership Urges Full Vaccination and All Measures to Protect Expecting Mothers and Children During COVID-19 Pandemic

Mednax (MD) and Brave Care form a relationship to provide enhanced pediatric care and pursue its pipeline of pediatric clinics' plan.

Mednax (MD) Invests in Brave Care to Boost Pediatric Business

PORTLAND, Ore., Oct. 7, 2021 /PRNewswire/ -- Brave Care, the first pediatric healthcare and technology platform dedicated to improving primary and urgent care for children, today announced it has raised $25M.

Brave Care, The Leader in Technology-Powered Pediatric Clinics, Raises $25M in Series B Investment led by Mednax, Inc.

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Mednax, Inc. and privately owned Brave Care will develop new, innovative pediatric primary and urgent care clinics throughout the United States.

Mednax and Brave Care to Accelerate Transformation of Pediatric Primary and Urgent Care

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #COVID19--Pediatrix® and Obstetrix® affiliated clinicians are treating more pregnant women critically ill with COVID-19 than at any point in the pandemic.

The Pediatrix® and Obstetrix® Medical Group Reports Surge in Critically Ill Pregnant Patients with the COVID-19 Delta Variant

Riding high on its revenue stream and strategic measures, MEDNAX (MD) holds potential to reap benefits for investors.

Here's Why You Should Retain MEDNAX (MD) in Your Portfolio

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Mednax to Present at Morgan Stanley 19th Annual Global Healthcare Conference

Mednax to Present at Morgan Stanley 19th Annual Global Healthcare Conference

MEDNAX's (MD) Q2 results reflect solid volumes, partly offset by escalating expenses.

MEDNAX's (MD) Earnings Beat Estimates in Q2, Improve Y/Y

MEDNAX, Inc. (MD) CEO Mark Ordan on Q2 2021 Results - Earnings Call Transcript

Mednax (MD) delivered earnings and revenue surprises of 24.24% and 3.72%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Mednax (MD) Beats Q2 Earnings and Revenue Estimates

Shares of Mednax (NYSE:MD) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share rose 28.12% year over year to $0.41, which beat the estimate of $0.32.

Mednax: Q2 Earnings Insights

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Mednax Reports Second Quarter Results

Mednax Reports Second Quarter Results

Mednax (NYSE:MD) releases its next round of earnings this Friday, August 06. Get the latest predictions in Benzinga's essential guide to the company's Q2 earnings report.

News for MEDNAX Stock (MD)